Total Payments
$36,187
2024 Payments
$28,231
Companies
16
Transactions
105
Payment Breakdown by Category
Consulting$24,070 (66.5%)
Travel$5,611 (15.5%)
Other$3,900 (10.8%)
Food & Beverage$2,607 (7.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $24,070 | 3 | 66.5% |
| Travel and Lodging | $5,611 | 23 | 15.5% |
| Honoraria | $3,900 | 1 | 10.8% |
| Food and Beverage | $2,607 | 78 | 7.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sarepta Therapeutics, Inc. | $29,666 | 43 | $0 (2024) |
| CATALYST PHARMACEUTICALS, INC. | $5,403 | 13 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $303.08 | 23 | $0 (2024) |
| Biogen, Inc. | $181.00 | 3 | $0 (2022) |
| Ipsen Biopharmaceuticals, Inc | $158.87 | 6 | $0 (2024) |
| Neurelis, Inc. | $117.24 | 4 | $0 (2024) |
| Novartis Gene Therapies, Inc. (fka AveXis, Inc.) | $104.98 | 2 | $0 (2023) |
| UCB, Inc. | $63.71 | 2 | $0 (2023) |
| PIRAMAL CRITICAL CARE | $43.45 | 2 | $0 (2023) |
| AveXis | $36.24 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $28,231 | 51 | Sarepta Therapeutics, Inc. ($22,623) |
| 2023 | $494.84 | 17 | Sarepta Therapeutics, Inc. ($125.37) |
| 2022 | $7,259 | 32 | Sarepta Therapeutics, Inc. ($6,918) |
| 2021 | $29.50 | 1 | Greenwich Biosciences, Inc. ($29.50) |
| 2020 | $17.16 | 1 | Zogenix Inc. ($17.16) |
| 2019 | $62.14 | 2 | AveXis ($36.24) |
| 2017 | $94.20 | 1 | Biogen, Inc. ($94.20) |
All Payment Transactions
105 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: EPILEPSY | ||||||
| 10/18/2024 | CATALYST PHARMACEUTICALS, INC. | AGAMREE (Drug) | Honoraria | Cash or cash equivalent | $3,900.00 | General |
| Category: NEUROLOGY | ||||||
| 10/18/2024 | CATALYST PHARMACEUTICALS, INC. | AGAMREE (Drug) | Travel and Lodging | Cash or cash equivalent | $64.87 | General |
| Category: NEUROLOGY | ||||||
| 10/18/2024 | CATALYST PHARMACEUTICALS, INC. | AGAMREE (Drug) | Travel and Lodging | Cash or cash equivalent | $56.08 | General |
| Category: NEUROLOGY | ||||||
| 10/18/2024 | CATALYST PHARMACEUTICALS, INC. | AGAMREE (Drug) | Food and Beverage | Cash or cash equivalent | $37.69 | General |
| Category: NEUROLOGY | ||||||
| 10/18/2024 | CATALYST PHARMACEUTICALS, INC. | AGAMREE (Drug) | Food and Beverage | Cash or cash equivalent | $33.00 | General |
| Category: NEUROLOGY | ||||||
| 10/18/2024 | CATALYST PHARMACEUTICALS, INC. | AGAMREE (Drug) | Food and Beverage | Cash or cash equivalent | $13.22 | General |
| Category: NEUROLOGY | ||||||
| 10/16/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $19.50 | General |
| 10/09/2024 | Sarepta Therapeutics, Inc. | Elevidys (Drug) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Genetic Disease | ||||||
| 10/09/2024 | Sarepta Therapeutics, Inc. | Elevidys (Drug) | Travel and Lodging | In-kind items and services | $45.95 | General |
| Category: Genetic Disease | ||||||
| 10/09/2024 | Sarepta Therapeutics, Inc. | Elevidys (Drug) | Food and Beverage | In-kind items and services | $35.54 | General |
| Category: Genetic Disease | ||||||
| 10/09/2024 | Sarepta Therapeutics, Inc. | Elevidys (Drug) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: Genetic Disease | ||||||
| 10/09/2024 | Sarepta Therapeutics, Inc. | Elevidys (Drug) | Travel and Lodging | In-kind items and services | $15.74 | General |
| Category: Genetic Disease | ||||||
| 10/09/2024 | Sarepta Therapeutics, Inc. | Elevidys (Drug) | Travel and Lodging | In-kind items and services | $10.91 | General |
| Category: Genetic Disease | ||||||
| 10/09/2024 | Sarepta Therapeutics, Inc. | Elevidys (Drug) | Travel and Lodging | In-kind items and services | $9.93 | General |
| Category: Genetic Disease | ||||||
| 10/09/2024 | Sarepta Therapeutics, Inc. | Elevidys (Drug) | Travel and Lodging | In-kind items and services | $5.00 | General |
| Category: Genetic Disease | ||||||
| 10/03/2024 | Sarepta Therapeutics, Inc. | Elevidys (Drug) | Consulting Fee | Cash or cash equivalent | $9,015.00 | General |
| Category: Genetic Disease | ||||||
| 09/28/2024 | CATALYST PHARMACEUTICALS, INC. | AGAMREE (Drug) | Food and Beverage | Cash or cash equivalent | $75.00 | General |
| Category: NEUROLOGY | ||||||
| 09/28/2024 | CATALYST PHARMACEUTICALS, INC. | AGAMREE (Drug) | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| Category: NEUROLOGY | ||||||
| 09/28/2024 | CATALYST PHARMACEUTICALS, INC. | AGAMREE (Drug) | Travel and Lodging | Cash or cash equivalent | $34.19 | General |
| Category: NEUROLOGY | ||||||
| 09/28/2024 | CATALYST PHARMACEUTICALS, INC. | AGAMREE (Drug) | Food and Beverage | Cash or cash equivalent | $25.00 | General |
| Category: NEUROLOGY | ||||||
| 09/27/2024 | CATALYST PHARMACEUTICALS, INC. | AGAMREE (Drug) | Travel and Lodging | Cash or cash equivalent | $814.93 | General |
| Category: NEUROLOGY | ||||||
| 09/27/2024 | CATALYST PHARMACEUTICALS, INC. | AGAMREE (Drug) | Travel and Lodging | Cash or cash equivalent | $181.26 | General |
| Category: NEUROLOGY | ||||||
| 09/27/2024 | CATALYST PHARMACEUTICALS, INC. | AGAMREE (Drug) | Travel and Lodging | Cash or cash equivalent | $117.84 | General |
| Category: NEUROLOGY | ||||||
| 09/14/2024 | Sarepta Therapeutics, Inc. | Elevidys (Drug) | Travel and Lodging | In-kind items and services | $250.00 | General |
| Category: Genetic Disease | ||||||
About Alexander Fay, M.D., PHD
Alexander Fay, M.D., PHD is a Pediatrics healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/11/2010. The National Provider Identifier (NPI) number assigned to this provider is 1760794424.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Alexander Fay, M.D., PHD has received a total of $36,187 in payments from pharmaceutical and medical device companies, with $28,231 received in 2024. These payments were reported across 105 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($24,070).
Ad
Practice Information
- Specialty Pediatrics
- Location Saint Louis, MO
- Active Since 07/11/2010
- Last Updated 07/11/2010
- Taxonomy Code 208000000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1760794424
Products in Payments
- Elevidys (Drug) $22,523
- AGAMREE (Drug) $5,403
- EPIDIOLEX (Drug) $303.08
- ZOLGENSMA (Biological) $141.22
- VALTOCO (Drug) $117.24
- Dysport (Drug) $88.72
- DYSPORT (Drug) $70.15
- Briviact (Drug) $63.71
- SPINRAZA (Biological) $60.16
- GABLOFEN (Drug) $43.45
- Epidiolex (Drug) $29.50
- TYSABRI (Biological) $26.64
- ZTALMY (Drug) $18.37
- Fintepla (Drug) $17.16
- Brineura (Biological) $15.45
- APTIOM (Drug) $10.09
- Exondys 51 (Drug) $9.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Saint Louis
Dr. Philip Spinella, Md, MD
Pediatrics — Payments: $286,187
Pediatrics $286,187
Dr. David Balzer, Md, MD
Pediatrics — Payments: $209,718
Pediatrics $209,718
Dr. Amy Clark, Do, DO
Pediatrics — Payments: $129,192
Pediatrics $129,192
Dr. Jennifer Silva, Md, MD
Pediatrics — Payments: $128,336
Pediatrics $128,336
Dr. Nico Dosenbach, Md, MD
Pediatrics — Payments: $115,400
Pediatrics $115,400
Dr. Kel Vin Woo, M.d., Ph.d, M.D., PH.D
Pediatrics — Payments: $100,017
Pediatrics $100,017